Affinity Asset Advisors LLC Invests $998,000 in OnKure Therapeutics, Inc. $OKUR

Affinity Asset Advisors LLC acquired a new stake in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 240,963 shares of the company’s stock, valued at approximately $998,000. Affinity Asset Advisors LLC owned 0.60% of OnKure Therapeutics at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. ADAR1 Capital Management LLC acquired a new position in shares of OnKure Therapeutics in the 4th quarter valued at $2,941,000. Shay Capital LLC boosted its position in shares of OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after acquiring an additional 135,888 shares in the last quarter. Prosight Management LP boosted its position in shares of OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after acquiring an additional 548,950 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in OnKure Therapeutics in the fourth quarter valued at about $2,118,000. Finally, Renaissance Technologies LLC increased its stake in OnKure Therapeutics by 52.5% in the first quarter. Renaissance Technologies LLC now owns 377,250 shares of the company’s stock valued at $1,562,000 after acquiring an additional 129,900 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $4.12 on Friday. OnKure Therapeutics, Inc. has a 52 week low of $1.91 and a 52 week high of $5.38. The company’s 50 day moving average price is $4.23 and its two-hundred day moving average price is $3.76. The company has a market capitalization of $166.45 million, a P/E ratio of -0.95 and a beta of 0.27.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37). Analysts forecast that OnKure Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on OKUR shares. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. JonesTrading downgraded OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright lowered their price target on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Weiss Ratings upgraded OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.